Criteria Based Consultation Prescribing Program
CRITERIA FOR DRUG COVERAGE
Evolocumab (Repatha)

Notes:
- Quantity limits: Yes
- *ASCVD=atherosclerotic cardiovascular disease; LDL=low-density lipoproteins; PST=patient support tool*

Non-formulary **evolocumab (Repatha)** will be covered on the prescription drug benefit when the following criteria are met:

Clinical ASCVD (examples include: heart attack or stroke)
- Prescribed by a cardiologist or an endocrinologist
- Age 40 to 85 years
- Receiving cholesterol lowering medications for at least 3 months including ezetimibe AND *statin therapy
- Statin adherence rate of greater than or equal to 85% that is verified from PST or pharmacy dispensing history
- Inadequate LDL reduction based on the statin intensity
- LDL greater than or equal to 70 mg/dL on statin therapy

***New members stable on evolocumab for at least 4 weeks or longer*:
- Receiving ezetimibe 10 mg/day unless patient suffered from recurrent ASCVD events
- LDL decreased by ≥ 50% on evolocumab compared to pre-evolocumab levels

Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)
- Prescribed by a cardiologist or an endocrinologist
- Age greater than or equal to 13 years for HoFH or 18 years for HeFH
- Not receiving LDL apheresis
- Receiving cholesterol lowering medications for at least 3 months including ezetimibe AND *statin therapy
- Statin adherence rate of greater than or equal to 85% that is verified from PST or pharmacy dispensing history
- LDL greater than or equal to 100 mg/dL within the last 3 months on statin and ezetimibe

***New members stable on evolocumab for at least 4 weeks or longer*:
- In addition to above criteria: LDL decreased by greater than or equal to 20% for HoFH or 50% for HeFH on evolocumab compared to pre-evolocumab levels

*Statin Therapy:
- Maximum dose of high intensity statin

Criteria Based Consultation Prescribing Program
CRITERIA FOR DRUG COVERAGE

Evolocumab (Repatha)

* Maximally tolerated dose equivalent to atorvastatin 20 mg/day with documentation of trials and intolerance of both atorvastatin and rosuvastatin
* Drug interaction precluding the use of atorvastatin 80 mg/day AND rosuvastatin 40 mg/day and the dose is at minimum equivalent to atorvastatin 20 mg/day